Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved]
Background: Maternal immunisation to boost respiratory syncytial virus (RSV) antibodies in pregnant women, is a strategy being considered to enhance infant protection from severe RSV associated disease. However, little is known about the efficiency of transplacental transfer of RSV-specific antibodi...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wellcome
2022-04-01
|
| Series: | Wellcome Open Research |
| Subjects: | |
| Online Access: | https://wellcomeopenresearch.org/articles/7-43/v2 |
| _version_ | 1818204395918065664 |
|---|---|
| author | Amek Nyaguara D James Nokes Joyce U. Nyiro Bryan Nyawanda Dufton Mwaengo Godfrey Bigogo Nancy Otieno Jennifer R. Verani Marc-Alain Widdowson Hope Mwangudza Sandra S. Chaves Patrick K. Munywoki Nickson Murunga James A. Berkley Elizabeth Bukusi Calleb Odundo |
| author_facet | Amek Nyaguara D James Nokes Joyce U. Nyiro Bryan Nyawanda Dufton Mwaengo Godfrey Bigogo Nancy Otieno Jennifer R. Verani Marc-Alain Widdowson Hope Mwangudza Sandra S. Chaves Patrick K. Munywoki Nickson Murunga James A. Berkley Elizabeth Bukusi Calleb Odundo |
| author_sort | Amek Nyaguara |
| collection | DOAJ |
| description | Background: Maternal immunisation to boost respiratory syncytial virus (RSV) antibodies in pregnant women, is a strategy being considered to enhance infant protection from severe RSV associated disease. However, little is known about the efficiency of transplacental transfer of RSV-specific antibodies in a setting with a high burden of malaria and HIV, to guide the implementation of such a vaccination program. Methods: Using a plaque reduction neutralization assay, we screened 400 pairs of cord and maternal serum specimens from pregnant women for RSV-specific antibodies. Participants were pregnant women of two surveillance cohorts: 200 participants from a hospital cohort in Kilifi, Coastal Kenya and 200 participants from a surveillance cohort in Siaya, Western Kenya. Transplacental transfer efficiency was determined by the cord to maternal titre ratio (CMTR). Logistic regression was used to determine independent predictors of impaired transplacental transfer of RSV-specific antibodies. Results: A total of 800 samples were screened from the 400 participants. At enrollment the median age was 25 years (Interquartile range (IQR): 21-31). Overall, transplacental transfer was efficient and did not differ between Kilifi and Siaya cohort (1.02 vs. 1.02; p=0.946) but was significantly reduced among HIV-infected mothers compared to HIV-uninfected mothers (mean CMTR: 0.98 vs 1.03; p=0.015). Prematurity <33 weeks gestation (Odds ratio [OR]: 0.23, 95% confidence interval [CI] 0.06–0.85; p=0.028), low birth weight <2.5 kgs (OR: 0.25, 95% CI: 0.07–0.94; p=0.041) and HIV infection (OR: 0.47, 95% CI:0.23-0.98; p=0.045) reduced efficiency of transplacental transfer among these women. Conclusions: Transplacental transfer of RSV-specific antibodies among pregnant women in Kenya is efficient. A consideration to integrate other preventive interventions with maternal RSV vaccination targeting infants born premature (<33 weeks gestation), with low birth weight <2.5 kgs, or HIV-infected mothers is likely to improve vaccine outcomes in this setting. |
| first_indexed | 2024-12-12T03:40:34Z |
| format | Article |
| id | doaj.art-4e6c759504a24c6e95eaf896af8ed73e |
| institution | Directory Open Access Journal |
| issn | 2398-502X |
| language | English |
| last_indexed | 2024-12-12T03:40:34Z |
| publishDate | 2022-04-01 |
| publisher | Wellcome |
| record_format | Article |
| series | Wellcome Open Research |
| spelling | doaj.art-4e6c759504a24c6e95eaf896af8ed73e2022-12-22T00:39:41ZengWellcomeWellcome Open Research2398-502X2022-04-01719709Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved]Amek Nyaguara0https://orcid.org/0000-0002-7865-8756D James Nokes1https://orcid.org/0000-0001-5426-1984Joyce U. Nyiro2https://orcid.org/0000-0001-7215-6539Bryan Nyawanda3Dufton Mwaengo4Godfrey Bigogo5Nancy Otieno6Jennifer R. Verani7Marc-Alain Widdowson8https://orcid.org/0000-0002-0682-6933Hope Mwangudza9https://orcid.org/0000-0003-1166-8965Sandra S. Chaves10https://orcid.org/0000-0002-9453-7057Patrick K. Munywoki11https://orcid.org/0000-0001-9419-7155Nickson Murunga12https://orcid.org/0000-0001-5304-2210James A. Berkley13https://orcid.org/0000-0002-1236-849XElizabeth Bukusi14Calleb Odundo15Centre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, KenyaInstitute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, KenyaCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, KenyaCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, KenyaInfluenza Division, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, USADivision of Global Health Protection, CDC-Kenya, U.S Centers for Disease Control and Prevention (CDC), Nairobi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaDivision of Global Health Protection, CDC-Kenya, U.S Centers for Disease Control and Prevention (CDC), Nairobi, KenyaDivision of Global Health Protection, CDC-Kenya, U.S Centers for Disease Control and Prevention (CDC), Nairobi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, KenyaCentre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, KenyaBackground: Maternal immunisation to boost respiratory syncytial virus (RSV) antibodies in pregnant women, is a strategy being considered to enhance infant protection from severe RSV associated disease. However, little is known about the efficiency of transplacental transfer of RSV-specific antibodies in a setting with a high burden of malaria and HIV, to guide the implementation of such a vaccination program. Methods: Using a plaque reduction neutralization assay, we screened 400 pairs of cord and maternal serum specimens from pregnant women for RSV-specific antibodies. Participants were pregnant women of two surveillance cohorts: 200 participants from a hospital cohort in Kilifi, Coastal Kenya and 200 participants from a surveillance cohort in Siaya, Western Kenya. Transplacental transfer efficiency was determined by the cord to maternal titre ratio (CMTR). Logistic regression was used to determine independent predictors of impaired transplacental transfer of RSV-specific antibodies. Results: A total of 800 samples were screened from the 400 participants. At enrollment the median age was 25 years (Interquartile range (IQR): 21-31). Overall, transplacental transfer was efficient and did not differ between Kilifi and Siaya cohort (1.02 vs. 1.02; p=0.946) but was significantly reduced among HIV-infected mothers compared to HIV-uninfected mothers (mean CMTR: 0.98 vs 1.03; p=0.015). Prematurity <33 weeks gestation (Odds ratio [OR]: 0.23, 95% confidence interval [CI] 0.06–0.85; p=0.028), low birth weight <2.5 kgs (OR: 0.25, 95% CI: 0.07–0.94; p=0.041) and HIV infection (OR: 0.47, 95% CI:0.23-0.98; p=0.045) reduced efficiency of transplacental transfer among these women. Conclusions: Transplacental transfer of RSV-specific antibodies among pregnant women in Kenya is efficient. A consideration to integrate other preventive interventions with maternal RSV vaccination targeting infants born premature (<33 weeks gestation), with low birth weight <2.5 kgs, or HIV-infected mothers is likely to improve vaccine outcomes in this setting.https://wellcomeopenresearch.org/articles/7-43/v2Pregnant women; transplacental transfer efficiency; Respiratory Syncytial Virus; Neutralising antibody Maternal vaccine Effectivenesseng |
| spellingShingle | Amek Nyaguara D James Nokes Joyce U. Nyiro Bryan Nyawanda Dufton Mwaengo Godfrey Bigogo Nancy Otieno Jennifer R. Verani Marc-Alain Widdowson Hope Mwangudza Sandra S. Chaves Patrick K. Munywoki Nickson Murunga James A. Berkley Elizabeth Bukusi Calleb Odundo Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] Wellcome Open Research Pregnant women; transplacental transfer efficiency; Respiratory Syncytial Virus; Neutralising antibody Maternal vaccine Effectiveness eng |
| title | Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] |
| title_full | Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] |
| title_fullStr | Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] |
| title_full_unstemmed | Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] |
| title_short | Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya [version 2; peer review: 2 approved] |
| title_sort | efficiency of transplacental transfer of respiratory syncytial virus rsv specific antibodies among pregnant women in kenya version 2 peer review 2 approved |
| topic | Pregnant women; transplacental transfer efficiency; Respiratory Syncytial Virus; Neutralising antibody Maternal vaccine Effectiveness eng |
| url | https://wellcomeopenresearch.org/articles/7-43/v2 |
| work_keys_str_mv | AT ameknyaguara efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT djamesnokes efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT joyceunyiro efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT bryannyawanda efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT duftonmwaengo efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT godfreybigogo efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT nancyotieno efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT jenniferrverani efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT marcalainwiddowson efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT hopemwangudza efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT sandraschaves efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT patrickkmunywoki efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT nicksonmurunga efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT jamesaberkley efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT elizabethbukusi efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved AT callebodundo efficiencyoftransplacentaltransferofrespiratorysyncytialvirusrsvspecificantibodiesamongpregnantwomeninkenyaversion2peerreview2approved |